for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cellectar Biosciences Inc

CLRB.OQ

Latest Trade

2.02USD

Change

-0.03(-1.46%)

Volume

303,817

Today's Range

1.99

 - 

2.08

52 Week Range

1.01

 - 

3.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.05
Open
2.07
Volume
303,817
3M AVG Volume
39.74
Today's High
2.08
Today's Low
1.99
52 Week High
3.31
52 Week Low
1.01
Shares Out (MIL)
27.26
Market Cap (MIL)
55.88
Forward P/E
-2.44
Dividend (Yield %)
--

Next Event

Cellectar Biosciences Inc Extraordinary Shareholders Meeting

Latest Developments

More

Cellectar Reports Q3 Loss Per Share Of $0.15

Cellectar Q2 Loss Per Share $0.26

Lincoln Park Capital Fund Reports 8.92% Passive Stake In Cellectar Biosciences, Inc As Of July 11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Industry

Biotechnology & Drugs

Contact Info

100 Campus Dr

FLORHAM PARK, NJ

07932-1020

United States

+1.608.4418120

http://cellectar.com

Executive Leadership

Douglas J. Swirsky

Independent Chairman of the Board

James V. Caruso

President, Chief Executive Officer, Director

Dov Elefant

Chief Financial Officer, Vice President

John E. Friend

Vice President, Chief Medical Officer

Jarrod Longcor

Chief Business Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-10.706

2018

-5.233

2019

-1.841

2020(E)

-0.828
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.13
LT Debt To Equity (MRQ)
1.13
Return on Investment (TTM)
-101.01
Return on Equity (TTM)
-81.74

Latest News

Latest News

BRIEF-Cellectar To Be Granted EU Patent For Phospholipid Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR TO BE GRANTED EU PATENT FOR PHOSPHOLIPID ETHER (PLE) ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage:

BRIEF-Aigh Capital Reports Passive Stake Of 6.52% In Cellectar Biosciences As Of June 3

* AIGH CAPITAL MANAGEMENT, LLC. REPORTS A PASSIVE STAKE OF 6.52% IN CELLECTAR BIOSCIENCES AS OF JUNE 3 - SEC FILING Source text: (https://bit.ly/2ARNezM) Further company coverage:

BRIEF-Cellectar Biosciences Announces Pricing Of $20 Million Underwritten Public Offering

* CELLECTAR BIOSCIENCES ANNOUNCES PRICING OF $20 MILLION UNDERWRITTEN PUBLIC OFFERING

BRIEF-Cellectar Granted SME Status By The European Medicines Agency

* CELLECTAR GRANTED SME STATUS BY THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

BRIEF-Cellectar Receives FDA Fast Track Designation For Clr 131 In Lymphoplasmacytic Lymphoma/Waldenstrom’S Macroglobulinemia

* CELLECTAR RECEIVES FDA FAST TRACK DESIGNATION FOR CLR 131 IN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM’S MACROGLOBULINEMIA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences Offering 11.9 Mln Common Shares, Pre-Funded Warrants To Purchase Common Shares, Warrants To Purchase 5.95 Mln Common Shares

* CELLECTAR BIOSCIENCES - OFFERING 11.9 MILLION COMMON SHARES, PRE-FUNDED WARRANTS TO PURCHASE COMMON SHARES, WARRANTS TO PURCHASE 5.95 MILLION COMMON SHARES Source text: [https://bit.ly/2zRu4JN] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Cellectar Biosciences Inc Files For Common Stock Offering Of Up To $17.5 Million - SEC Filing

* CELLECTAR BIOSCIENCES INC FILES FOR COMMON STOCK OFFERING OF UP TO $17.5 MILLION - SEC FILING Source text for Eikon: https://bit.ly/2YXM4wP Further company coverage:

BRIEF-Cellectar Reports Financial Results For Year Ended December 31, 2019 And Provides A Corporate Update

* CELLECTAR REPORTS FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2019 AND PROVIDES A CORPORATE UPDATE

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions

* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up